We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Anti-HEV Assays Evaluated for Diagnosing Acute Hepatitis E Infections

By LabMedica International staff writers
Posted on 04 Dec 2013
The performance of two anti-HEV IgG and IgM assays were assessed for diagnosing acute HEV infections in immunocompromised patients.

Hepatitis E virus is an emerging concern in immunocompromised patients, who may become chronically infected. More...
No data were available for immunocompromised patients, who might not mount a good antibody response to HEV and might thus test negative for anti-HEV antibodies. The two anti-HEV assays evaluated in the study, published in the Journal of Clinical Virology online ahead of print October 15, 2013, were those from Adaltis and Wantai, the two main serological assays employed in Europe, specifically: EIAgen HEV IgG and IgM kits (Adaltis; Eurobio, France), based on synthetic antigens encoded by the ORF2 and ORF3 genes of HEV1 and HEV2; and the HEVIgM and IgG ELISA 3.0 Wantai kits (Wantai Biological Pharmacy Enterprise Co.; China), based on a recombinant HEV1 antigen, pE2. Tests were performed as recommended by the manufacturers.

Specificities were estimated by testing samples from 2 to 3 year-old children and blood donors and sensitivities were estimated by testing 40 immunocompromised patients acutely infected. Both anti-HEV IgM assays were highly specific (99.6% and 100%). The sensitivity of the Adaltis was 87.5%, and that of Wantai was 85%. The specificities of anti-HEV IgG Wantai (97.8%) and Adaltis tests (89.5%, = 0.1) were similar but the Wantai test was more sensitive (45%) than the Adaltis test (15%, < 0.001). None of the samples was anti-HEV IgM negative and IgG positive.

The authors, led by Dr. Florence Abravanel of the Centre Hospitalier Universitaire de Toulouse (University Hospital Center of Toulouse; Toulouse, France), concluded that these anti-HEV IgM assays performed well in immunosuppressed patients with acute hepatitis E and can be used as first line virological tools. Testing for anti-HEV IgG and IgM simultaneously at the acute phase did not improve the diagnostic performance. In contrast, molecular detection of HEV RNA appears essential to exclude an HEV infection in patients who are negative for anti-HEV IgM and to assess the evolution of hepatitis E three months thereafter.

Related Links:

Centre Hospitalier Universitaire de Toulouse



New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.